TransMedics Group, Inc. $TMDX Shares Acquired by Creative Planning

Creative Planning boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 60.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,597 shares of the company’s stock after purchasing an additional 6,999 shares during the quarter. Creative Planning owned about 0.05% of TransMedics Group worth $2,492,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMDX. Amalgamated Bank boosted its holdings in shares of TransMedics Group by 0.8% in the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after buying an additional 80 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after acquiring an additional 135 shares during the last quarter. CWM LLC boosted its stake in TransMedics Group by 20.1% in the first quarter. CWM LLC now owns 925 shares of the company’s stock valued at $62,000 after acquiring an additional 155 shares in the last quarter. Maryland State Retirement & Pension System grew its holdings in shares of TransMedics Group by 1.9% during the second quarter. Maryland State Retirement & Pension System now owns 9,943 shares of the company’s stock worth $1,332,000 after purchasing an additional 185 shares during the last quarter. Finally, Opal Wealth Advisors LLC purchased a new position in shares of TransMedics Group during the second quarter worth about $26,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Up 7.1%

Shares of TransMedics Group stock opened at $140.21 on Tuesday. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $145.50. The company has a market cap of $4.79 billion, a P/E ratio of 56.77 and a beta of 2.05. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The firm has a fifty day moving average of $120.65 and a two-hundred day moving average of $121.41.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business had revenue of $143.82 million for the quarter, compared to the consensus estimate of $145.33 million. During the same quarter in the previous year, the firm earned $0.12 earnings per share. The business’s quarterly revenue was up 32.2% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total transaction of $540,323.90. Following the transaction, the director owned 2,866 shares in the company, valued at approximately $373,869.70. The trade was a 59.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 7.00% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TMDX shares. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Stifel Nicolaus started coverage on TransMedics Group in a research note on Thursday, September 4th. They issued a “hold” rating and a $115.00 price objective for the company. Canaccord Genuity Group raised their target price on shares of TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a report on Thursday, October 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.